Used in the treatment of advanced non-small cell lung cancer (NSCLC), this antibody works by blocking the PD-1 receptor on T-cells, thereby enhancing the immune system’s ability to detect and destroy cancer cells. It is indicated for patients who have progressed on or after platinum-based chemotherapy, with or without targeted therapy or immunotherapy. Clinical trials have shown improved progression-free survival and overall response rates, particularly in patients whose tumors express PD-L1. The antibody is administered intravenously and is part of a growing class of immune checkpoint inhibitors used in oncology to restore anti-tumor immune responses. It may also be under investigation for use in other solid tumors, including gastric, esophageal, and hepatocellular carcinomas.